BMS 900 million US dollars to build a factory in Ireland

Source: fierce Pharma on November 18, 2014, Bristol Myers Squibb began to look for a new production base in view of the growth of biological agents yevoy and Stacey On November 14, Dublin, Ireland, was compared by BMS, with an estimated investment of $900 million and 400 new jobs It is reported that the plant will mainly produce biological agents, covering an area of 320000 square feet (about 14000 mu), and is expected to be completed in 2019 "For BMS, biologics account for more than half of the main business at present," said CEO Lamberto Andreotti "This investment reflects BMS's determination to increase its code in the future." Despite a 4% year-on-year decline in sales in the third quarter, the company did not let industry analysts lose heart Take a look at the company's leading products: yevoy, an anti-tumor drug, has a year-on-year growth of 47%, with sales of $350 million; dasatinib has a growth rate of 22%, with sales of $385 million; orencia, a rheumatoid arthritis injection, has a year-on-year growth of 18%, with sales of $444 million It is reported that orencia's production plant is located in Devons, Massachusetts, USA, covering an area of 400000 square feet, which was opened in 2012 The factory has 300 employees At present, macromolecular drugs are becoming more and more important in the product line of large pharmaceutical companies: in 2013, Roche spent a total of $900 million on the factory expansion plan: among them, a new factory was built in Switzerland, and the production scale was expanded in Germany and the United States It is expected that Roche will add 500 new positions after the completion of the expansion plan